Cargando…

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects

BACKGROUND: In Japan, dipeptidyl peptidase 4 (DPP4) inhibitors have become standard therapeutic agents for type 2 diabetes, and numbers of patients receiving insulin therapy combined with DPP4 inhibitors, which is a highly effective regimen, are increasing. METHODS: In this study, we evaluated the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Daisuke, Inoue, Kazuyuki, Kaneko, Kimie, Yanagisawa, Morifumi, Sumita, Takashi, Ikegami, Yuichi, Awata, Takuya, Ishida, Hitoshi, Katayama, Shigehiro, Inukai, Kouichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356089/ https://www.ncbi.nlm.nih.gov/pubmed/25780477 http://dx.doi.org/10.14740/jocmr2057w

Ejemplares similares

Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2018)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Adiponectin Upregulates Ferritin Heavy Chain in Skeletal Muscle Cells
por: Ikegami, Yuichi, et al.
Publicado: (2009)

Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
por: Ito, Daisuke, et al.
Publicado: (2021)

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
por: Ito, Daisuke, et al.
Publicado: (2015)

A Novel Splicing Variant of Peroxisome Proliferator-Activated Receptor-γ (Pparγ1sv) Cooperatively Regulates Adipocyte Differentiation with Pparγ2
por: Takenaka, Yasuhiro, et al.
Publicado: (2013)

Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine
por: Nakano, Takanari, et al.
Publicado: (2016)

Feminizing Adrenocortical Carcinoma with Distinct Histopathological Findings
por: Hatano, Masako, et al.
Publicado: (2016)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Vildagliptin-induced acute lung injury: a case report
por: Ohara, Nobumasa, et al.
Publicado: (2016)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
por: Chang, Jin-Sun, et al.
Publicado: (2013)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals
por: NOGUCHI, KAORU, et al.
Publicado: (2015)

Possible Effect of Concomitant Prokinetics and Herbal Medicines against Nausea in Patients Taking Lubiprostone
por: Yamamoto, Takatsugu, et al.
Publicado: (2017)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Anaerobic Dechlorination by a Humin-Dependent Pentachlorophenol-Dechlorinating Consortium under Autotrophic Conditions Induced by Homoacetogenesis
por: Laskar, Mahasweta, et al.
Publicado: (2019)

Humin Assists Reductive Acetogenesis in Absence of Other External Electron Donor
por: Laskar, Mahasweta, et al.
Publicado: (2020)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
por: Ito, Hiroyuki, et al.
Publicado: (2013)

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
por: van Poppel, Pleun C.M., et al.
Publicado: (2011)

Spectrophotometric Methods for the Determination of Sitagliptin and Vildagliptin in Bulk and Dosage Forms
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
por: Zhang, Qian, et al.
Publicado: (2017)

Renoprotective effect of vildagliptin following hepatic ischemia/reperfusion injury
por: Sherif, Iman O., et al.
Publicado: (2020)

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j10rn3si2do9rq9vlj7rshu9s6